

UK INTERDISCIPLINARY BREAST CANCER SYMPOSIUM

15TH-16TH JANUARY 2018

MANCHESTER CENTRAL CONVENTION CENTRE

DRAFT PROGRAMME AT A GLANCE

Updated 29/8/17

MONDAY 15TH JANUARY 2018

	Auditorium	Charter 1	Charter 2 & 3
09.00 – 09.10	Opening Professor Mitch Dowsett		
09.10 – 10.30	Highlights of 2017 Basic Translational Early Disease Late Disease Professor Clare Isacke Professor Peter Schmid Professor Michael Gnant Dr Mark Verrill		
10.30 – 11.00	LeCure lecture: <i>Chair:</i> Breast Cancer Research: Past and Future Dr Marc Lippman Professor Ian Smith		
11.05 – 11.25	Coffee break		
11.30 – 12.50	Metastatic Disease Managing ER+ Disease Professor Stephen Johnston Predicting outcome in metastatic breast cancer Dr Aleix Prat Evolution of resistance Dr Adrian Harris Abstract presentation	Ductal Carcinoma In Situ How should we address overdiagnosis and overtreatment of DCIS? Dr Laura Esserman How wide a margin do we need for DCIS? Professor Sarah Pinder Should radiotherapy be routinely recommended after wide local excision of DCIS? Professor David Dodwell Abstract presentation	Model systems PDX models Organoid models 3D in vitro modelling using material from Breast Cancer Now Tissue Bank Dr Rob Clarke Dr Mathew Garnett Dr Richard Grose

UK INTERDISCIPLINARY BREAST CANCER SYMPOSIUM

15TH-16TH JANUARY 2018

MANCHESTER CENTRAL CONVENTION CENTRE

12.55 – 13.55	Lunch break	Industry Symposia	Industry Symposia
14.00 – 14.30	Key note lecture: Dr Laura Esserman Innovation in neoadjuvant chemotherapy		
14.35 – 15.55	Neoadjuvant therapy <i>Chair: Professor Ian Smith</i> Neoadjuvant therapy as a surgical tool Professor Mike Dixon Treatment of the axilla post neoadjuvant chemotherapy Dr Judy Boughey <i>Neera Patel Lecture: RCB vs pCR as an end-point</i> Dr Fraser Symmans Latest data on imaging end-points for neoadjuvant therapy Dr Sarah Vinnicombe	A practical guide to shared decision making: Putting research into practice <i>Chairs: Professor Debbie Fenlon Lesley Turner</i> The benefits of shared decision making Professor Diana Harcourt What can help to help make a good decision in a difficult situation like breast cancer? Dr Alex Clarke Tools available to support shared decision making Dr Nicole Paraskeva	Image analysis for scientists and pathologists Imaging-based analysis of ErbB/HER signaling dimer and immunoregulatory molecules – from preclinical science to biomarker discovery Professor Tony Ng Image analysis for capturing stromal epithelial interaction Dr Yinyin Yuan Using digital pathology in translational breast cancer research Professor Valerie Speirs
15.55 – 16.15	Coffee break	Coffee break	Coffee break
16.20 – 17.40	Abstract session	Novel Clinical Trial End-points Why do we need better trial end-points? Professor Judith Bliss Novel trial endpoints: Opportunities & challenges for new surrogate endpoints Dr Marc Buyse	Costs of treatment <i>Chairs: Professor Arnie Purushotham Mrs Ursula van Mann</i> From price to value: Keeping breast cancer care affordable Professor Richard Sullivan Critically examining the true value of our therapies: The only way to meaningful gains in breast cancer Professor Tito Fojo
17.45 – 18.15	Key note lecture: Professor Sir David Spiegelhalter Understanding Risk		

18.15 – 19.15: Drinks reception and poster viewing: Exhibition Hall

UK INTERDISCIPLINARY BREAST CANCER SYMPOSIUM

15TH-16TH JANUARY 2018

MANCHESTER CENTRAL CONVENTION CENTRE

TUESDAY 16TH JANUARY 2018

	Auditorium	Charter 1	Charter 2 & 3
07.45 – 08.45		Industry Symposia	Industry Symposia
09.00 – 09.30	Key note lecture sponsored by BACR: Professor Jack Cuzick Breast Cancer Prevention for the Population at Large		
09.40 – 11.00	Measuring and managing breast cancer risk Stratification to screening Professor Fiona Gilbert Risk prediction for risk reduction Professor Gareth Evans Findings from the Generations study Professor Tony Swerdlow Identifying genetic risk in the prevalent breast cancer population Professor Nazneen Rahman	Triple Negative Breast Cancer Biology of the new targets Professor Andrew Tutt Complexities of TNTs Dr Chuck Perou Immunologic advances Dr Giuseppe Curigliano	Breast Cancer Heterogeneity and Evolution Genetic aspects Dr Lucy Yates Experimental modelling of heterogeneity Dr Rachael Natrajan Relevance to the histopathologist Dr Fraser Symmans
11.05 – 11.30	Coffee break	Coffee break	Coffee break
11.35 – 12.55	New treatments and measuring their impact CDK4/6 inhibition Dr Nick Turner New Selective Oestrogen Receptor Downregulators (SERDS) Dr Lesley-Ann Martin	Lobular breast cancer Chair: Professor David Dodwell Biologic aspects Dr Steffi Oesterreich Genetic aspects Dr Elinor Sawyer Histologic dilemmas Professor Ian Ellis	Communicating risk in the context of genomic testing Professor Sir David Spiegelhalter Dame Lesley Fallowfield

UK INTERDISCIPLINARY BREAST CANCER SYMPOSIUM

15TH-16TH JANUARY 2018

MANCHESTER CENTRAL CONVENTION CENTRE

	Liquid biopsies Professor Jacqui Shaw	Should lobular phenotype be considered when deciding treatment? Professor Michael Kerin	
13.00 – 14.00	Lunch break	Industry Symposia	Industry symposia
14.05 – 14.35	Cridlan lecture: Dr Chuck Perou Completion of the Cancer Genome Atlas		
14.40 – 16.00	Biomarkers and prognostic profiling Lessons from molecular subtyping Professor Carlos Caldas Clinical utility of molecular profiles Professor Rob Stein Identifying who needs extended adjuvant ET Dr Dan Hayes Mutation-directed therapy Professor Fabrice André	Challenges of local management Management and follow up of patients presenting with breast cancer in axillary lymph nodes and occult breast primary Dr Andreas Makris When is local surgery indicated in metastatic breast cancer? Miss Nicola Roche What is the impact of MRI scanning on breast cancer treatment? Prof Ulrich Bick Current and future indications for partial breast radiotherapy Dr Charlotte Coles	Clinical Trials Roadshow, chaired by Professor Dan Rea
16.10 – 16.40	Key note lecture: Professor David Cameron Achievements of Breast Cancer Research in the UK		
16.40	CLOSING REMARKS Professor Mitch Dowsett		